Bone loss and vascular calcification: A bi-directional interplay?

Vascular Pharmacology

Volumn 86, Issue , 2016, Pages 77-86

  Vassalle, Cristina ^a   Mazzone, Annamaria ^a  

^a CNR   (Italy)

Author keywords

Cardiovascular disease; Cross talk; Osteoporosis; Vascular calcification

Indexed keywords

CATHEPSIN K; FETUIN A; FIBROBLAST GROWTH FACTOR 23; MINERAL; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; VITAMIN D; BIOLOGICAL MARKER;

BLOOD VESSEL CALCIFICATION; CELL DIFFERENTIATION; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; AGING; ANIMAL; BONE; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; VASCULAR DISEASE;

AGING; ANIMALS; BIOMARKERS; BONE AND BONES; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; OSTEOPOROSIS; OXIDATIVE STRESS; VASCULAR CALCIFICATION; VASCULAR DISEASES;

EID: 84979663274     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2016.07.003     Document Type: Review

References (187)

1. [1] Vassalle, C., Maffei, S., Iervasi, G., Bone remodeling biomarkers: new actors on the old cardiovascular stage. Biomarker Validation – Technological, Clinical and Commercial Aspects, Feb 2015 27, Wiley-VCH Verlag GmbH & Co. KGaA, 107–146 (Published Online:, Chapter 7).
2. [2] Evrard, S., Delanaye, P., Kamel, S., Cristol, J.P., Cavalier, E., SFBC/SN joined working group on vascular calcifications. Vascular calcification: from pathophysiology to biomarkers. Clin. Chim. Acta 438 (2015), 401–414.
3. [3] Pal, S.N., Golledge, J., Osteo-progenitors in vascular calcification: a circulating cell theory. J. Atheroscler. Thromb. 18 (2011), 551–559.
4. [4] Tang, Z., Wang, A., Yuan, F., Yan, Z., Liu, B., Chu, J.S., et al. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat. Commun., 3, 2012, 875.
5. [5] Tintut, Y., Abedin, M., Cho, J., Choe, A., Lim, J., Demer, L.L., Regulation of RANKL-induced osteoclastic differentiation by vascular cells. J. Mol. Cell. Cardiol. 39 (2005), 389–393.
6. [6] Demer, L.L., Tintut, Y., Vascular calcification: pathobiology of a multifaceted disease. Circulation 117 (2008), 2938–2948.
7. [7] Pai, A., Leaf, E.M., El-Abbadi, M., Giachelli, C.M., Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am. J. Pathol. 178 (2011), 764–773.
8. [8] Jono, S., Shioi, A., Ikari, Y., Nishizawa, Y., Vascular calcification in chronic kidney disease. J. Bone Miner. Metab. 24 (2006), 176–181.
9. [9] Sonou, T., Ohya, M., Yashiro, M., Masumoto, A., Nakashima, Y., Ito, T., et al. Mineral composition of phosphate-induced calcification in a rat aortic tissue culture model. J. Atheroscler. Thromb., 27, Jun 2015 ([Epub ahead of print] PubMed PMID: 26119071).
10. [10] Lee, K.S., Kim, H.J., Li, Q.L., Chi, X.Z., Ueta, C., Komori, T., et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol. Cell. Biol. 20 (2000), 8783–8792.
11. [11] Villa-Bellosta, R., Millan, A., Sorribas, V., Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am. J. Phys. Cell Physiol. 300 (2011), C210–C220.
12. [12] Chavkin, N.W., Chia, J.J., Crouthamel, M.H., Giachelli, C.M., Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells. Exp. Cell Res. 333 (2015), 39–48.
13. [13] Sage, A.P., Lu, J., Tintut, Y., Demer, L.L., Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int. 79 (2011), 414–422.
14. [14] Villa-Bellosta, R., Vascular calcification revisited: a new perspective for phosphate transport. Curr. Cardiol. Rev., 5, Aug 2015 ([Epub ahead of print] PubMed PMID: 26242187).
15. [15] Lomashvili, K.A., Narisawa, S., Millán, J.L., O'Neill, W.C., Vascular calcification is dependent on plasma levels of pyrophosphate. Kidney Int. 85 (2014), 1351–1356.
16. [16] Palmer, S.C., Hayen, A., Macaskill, P., Pellegrini, F., Craig, J.C., Elder, G.J., et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305 (2011), 1119–1127.
17. [17] Hod, T., Riella, L.V., Chandraker, A., Recombinant PTH therapy for severe hypoparathyroidism after kidney transplantation in pre-transplant parathyroidectomized patients: review of the literature and a case report. Clin. Transpl., Aug 31 2015, 10.1111/ctr.12622.
18. [18] Sebastian, E.M., Suva, L.J., Friedman, P.A., Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone 43 (2008), 1022–1030.
19. [19] Jean, G., Bresson, E., Lorriaux, C., Mayor, B., Hurot, J.M., Deleaval, P., et al. Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients. Nephron Clin. Pract. 120 (2012), 132–138.
20. [20] Jung, J.Y., Hwang, Y.H., Lee, S.W., Lee, H., Kim, D.K., Kim, S., et al. Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. Nephrol. Dial. Transplant. 25 (2010), 4041–4048.
21. [21] Graciolli, F.G., Neves, K.R., dos Reis, L.M., Graciolli, R.G., Noronha, I.L., Moysés, R.M., et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol. Dial. Transplant. 24 (2009), 1416–1421.
22. [22] Blau, J.E., Collins, M.T., The PTH-Vitamin D-FGF23 axis. Rev. Endocr. Metab. Disord. 16 (2015), 165–174.
23. [23] Yang, D., Turner, A.G., Wijenayaka, A.R., Anderson, P.H., Morris, H.A., Atkins, G.J., 1, 25-Dihydroxyvitamin D3 and extracellular calcium promote mineral deposition via NPP1 activity in a mature osteoblast cell line MLO-A5. Mol. Cell. Endocrinol. 412 (2015), 140–147.
24. [24] Mary, A., Hénaut, L., Boudot, C., Six, I., Brazier, M., Massy, Z.A., et al. Calcitriol prevents in vitro vascular smooth muscle cell mineralization by regulating calcium-sensing receptor expression. Endocrinology 156 (2015), 1965–1974.
25. [25] Osako, M.K., Nakagami, H., Koibuchi, N., Shimizu, H., Nakagami, F., Koriyama, H., et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ. Res. 107 (2010), 466–475.
26. [26] Liu, G.Y., Liang, Q.H., Cui, R.R., Liu, Y., Wu, S.S., Shan, P.F., et al. Leptin promotes the osteoblastic differentiation of vascular smooth muscle cells from female mice by increasing RANKL expression. Endocrinology 155 (2014), 558–567.
27. [27] Lu, Y., Bian, Y., Wang, Y., Bai, R., Wang, J., Xiao, C., Globular adiponectin reduces vascular calcification via inhibition of ER-stress-mediated smooth muscle cell apoptosis. Int. J. Clin. Exp. Pathol. 8 (2015), 2545–2554.
28. [28] Zhan, J.K., Wang, Y.J., Wang, Y., Wang, S., Tan, P., Huang, W., et al. The mammalian target of rapamycin signalling pathway is involved in osteoblastic differentiation of vascular smooth muscle cells. Can. J. Cardiol. 30 (2014), 568–575.
29. [29] Zhan, J.K., Wang, Y.J., Wang, Y., Tang, Z.Y., Tan, P., Huang, W., et al. Adiponectin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the AMPK/mTOR pathway. Exp. Cell Res. 323 (2014), 352–358.
30. [30] Hyder, J.A., Allison, M.A., Criqui, M.H., Wright, C.M., Association between systemic calcified atherosclerosis and bone density. Calcif. Tissue Int. 80 (2007), 301–306.
31. [31] Schousboe, J.T., Taylor, B.C., Kiel, D.P., Ensrud, K.E., Wilson, K.E., McCloskey, E.V., Abdominal aortic calcification detected on lateral spine images from a bone densitometer predicts incident myocardial infarction or stroke in older women. J. Bone Miner. Res. 23 (2008), 409–416.
32. [32] Bagger, Y.Z., Tankó, L.B., Alexandersen, P., Qin, G., Christiansen, C., Prospective Epidemiological Risk Factors Study Group, Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J. Intern. Med. 259 (2006), 598–605.
33. [33] Hyder, J.A., Allison, M.A., Wong, N., Papa, A., Lang, T.F., Sirlin, C., et al. Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study. Am. J. Epidemiol. 169 (2009), 186–194.
34. [34] Farhat, G.N., Cauley, J.A., Matthews, K.A., Newman, A.B., Johnston, J., Mackey, R., et al. Volumetric BMD and vascular calcification in middle-aged women: the Study of Women's Health Across the Nation. J. Bone Miner. Res. 21 (2006), 1839–1846.
35. [35] Kiel, D.P., Kauppila, L.I., Cupples, L.A., Hannan, M.T., O'Donnell, C.J., Wilson, P.W., Bone Loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif. Tissue Int. 68 (2001), 271–276.
36. [36] Hak, A.E., Pols, H.A., van Hemert, A.M., Hofman, A., Witteman, J.C., Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler. Thromb. Vasc. Biol. 20 (2000), 1926–1931.
37. [37] Schulz, E., Arfai, K., Liu, X., Sayre, J., Gilsanz, V., Aortic calcification and the risk of osteoporosis and fractures. J. Clin. Endocrinol. Metab. 89 (2004), 4246–4253.
38. [38] Simon, S.P., Fodor, D., Muntean, L., Poanta, L., Cristea, P., Rednic, S., Bone mineral density, vertebral fractures and body mass index in postmenopausal women with abdominal aortic calcification. Endocr. Res. 39 (2014), 1–6.
39. [39] Samelson, E.J., Cupples, L.A., Broe, K.E., Hannan, M.T., O'Donnell, C.J., Kiel, D.P., Vascular calcification in middle age and long-term risk of hip fracture: the Framingham Study. J. Bone Miner. Res. 22 (2007), 1449–1454.
40. [40] Vogt, M.T., San Valentin, R., Forrest, K.Y., Nevitt, M.C., Cauley, J.A., Bone mineral density and aortic calcification: the Study of Osteoporotic Fractures. J. Am. Geriatr. Soc. 45 (1997), 140–145.
41. [41] Aoyagi, K., Ross, P.D., Orloff, J., Davis, J.W., Katagiri, H., Wasnich, R.D., Low bone density is not associated with aortic calcification. Calcif. Tissue Int. 69 (2001), 20–24.
42. [42] den Uyl, D., Nurmohamed, M.T., van Tuyl, L.H., Raterman, H.G., Lems, W.F., (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res. Ther., 13, 2011, R5.
43. [43] Jorgensen, L., Joakimsen, O., Rosvold Berntsen, G.K., Heuch, I., Jacobsen, B.K., Low bone mineral density is related to echogenic carotid artery plaques: a population-based study. Am. J. Epidemiol. 160 (2004), 549–556.
44. [44] Värri, M., Tuomainen, T.P., Honkanen, R., Rikkonen, T., Niskanen, L., Kröger, H., et al. Carotid intima-media thickness and calcification in relation to bone mineral density in postmenopausal women-the OSTPRE-BBA study. Maturitas 78 (2014), 304–309.
45. [45] Doherty, T.M., Fitzpatrick, L.A., Inoue, D., Qiao, J.H., Fishbein, M.C., Detrano, R.C., et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr. Rev. 25 (2004), 629–672.
46. [46] Chen, N.X., Moe, S.M., Pathophysiology of vascular calcification. Curr. Osteoporos. Rep., Sep 26 2015 ([Epub ahead of print] PubMed PMID: 26409849).
47. [47] Yiu, A.J., Callaghan, D., Sultana, R., Bandyopadhyay, B.C., Vascular calcification and stone disease: a new look towards the mechanism. J. Cardiovasc. Dev. Dis. 2 (2015), 141–164.
48. [48] Vassalle, C., Iervasi, G., Cathepsin K–a classical bone biomarker in cardiovascular disease: the heart is not alone anymore. Atherosclerosis 228 (2013), 36–37.
49. [49] Turk, V., Turk, B., Turk, D., Lysosomal cysteine proteases: facts and opportunities. EMBO J. 20 (2001), 4629–4633.
50. [50] Gelb, B.D., Shi, G.P., Chapman, H.A., Desnick, R.J., Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273 (1996), 1236–1238.
51. [51] Saftig, P., Hunziker, E., Everts, V., et al. Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. Adv. Exp. Med. Biol. 477 (2000), 293–303.
52. [52] Aikawa, E., Nahrendorf, M., Figueiredo, J.L., Swirski, F.K., Shtatland, T., Kohler, R.H., et al. Osteogenesis associates with inflammation in early-stage atherosclerosis imaging in vivo. Circulation 116 (2007), 2841–2850.
53. [53] Lutgens, E., Lutgens, S.P., Faber, B.C., Heeneman, S., Gijbels, M.M., de Winther, M.P., et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 113 (2006), 98–107.
54. [54] Sukhova, G.K., Shi, G.P., Simon, D.I., Chapman, H.A., Libby, P., Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest., 576–83, 1998.
55. [55] Barascuk, N., Skjøt-Arkil, H., Register, T.C., Larsen, L., Byrjalsen, I., Christiansen, C., et al. Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes. BMC Cardiovasc. Disord., 10, 2010, 19.
56. [56] Helske, S., Syvaranta, S., Lindstedt, K.A., Lappalainen, J., Oorni, K., Mayranpaa, M.I., et al. Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler. Thromb. Vasc. Biol. 26 (2006), 1791–1798.
57. [57] Cheng, X.W., Kikuchi, R., Ishii, H., Yoshikawa, D., Hu, L., Takahashi, R., et al. Circulating CatK as a potential novel biomarker of coronary artery disease. Atherosclerosis 228 (2013), 211–216.
58. [58] Han, J., Luo, T., Gu, Y., Li, G., Jia, W., Luo, M., Cathepsin K regulates adipocyte differentiation: possible involvement of type I collagen degradation. Endocr. J. 56 (2009), 55–63.
59. [59] Herrero, S., Pico, Y., Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?. Eur. J. Pharmacol., Feb 25 2016, 10.1016/j.ejphar.2016.02.053 (pii:S0014-2999(16)30098-X).
60. [60] Duong, L.T., Leung, A.T., Langdahl, B., Cathepsin K inhibition: a new mechanism for the treatment of osteoporosis. Calcif. Tissue Int., 3, 2015 Sep ([Epub ahead of print] PubMed PMID: 26335104).
61. [61] Schultz, T.C., Valenzano, J.P., Verzella, J.L., Umland, E.M., Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis. Women's Health (Lond. Engl.), Sep 7 2015.
62. [62] Simonet, W.S., Lacey, D.L., Dunstan, C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:2 (1997), 309–319.
63. [63] Callegari, A., Coons, M.L., Ricks, J.L., Rosenfeld, M.E., Scatena, M., Increased calcification in osteoprotegerin-deficient smooth muscle cells: dependence on receptor activator of NF-kB ligand and interleukin 6. J. Vasc. Res. 51 (2014), 118–131.
64. [64] Yun, T.J., Tallquist, M.D., Aicher, A., Rafferty, K.L., Marshall, A.J., Moon, J.J., et al. Osteoprotegerin a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 166 (2001), 1482–1491.
65. [65] Tella, S.H., Gallagher, J.C., Prevention and treatment of postmenopausal osteoporosis. J. Steroid Biochem. Mol. Biol. 142 (Jul 2014), 155–170.
66. [66] Bucay, N., Sarosi, I., Dunstan, C.R., Morony, S., Tarpley, J., Capparelli, C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12 (1998), 1260–1268.
67. [67] Sandberg, W.J., Yndestad, A., Øie, E., Smith, C., Ueland, T., Ovchinnikova, O., et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler. Thromb. Vasc. Biol. 26 (2006), 857–863.
68. [68] Bennett, B.J., Scatena, M., Kirk, E.A., Rattazzi, M., Varon, R.M., Averill, M., et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol. 26 (2006), 2117–2124.
69. [69] Golledge, J., McCann, M., Mangan, S., Lam, A., Karan, M., Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35 (2004), 1636–1641.
70. [70] Davaine, J.M., Quillard, T., Brion, R., Lapérine, O., Guyomarch, B., Merlini, T., et al. Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability. PLoS One, 9, 2014, e107642.
71. [71] Albu, A., Bondor, C.I., Crăciun, A.M., Fodor, D., Circulating osteoprotegerin and asymptomatic carotid atherosclerosis in postmenopausal non diabetic women. Adv. Med. Sci. 59 (2014), 293–298.
72. [72] Tousoulis, D., Siasos, G., Maniatis, K., Oikonomou, E., Kioufis, S., Zaromitidou, M., et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int. J. Cardiol. 167 (2013), 1924–1928.
73. [73] Pérez de Ciriza, C., Lawrie, A., Varo, N., Osteoprotegerin in cardiometabolic disorders. Int. J. Endocrinol., 2015, 2015, 564934.
74. [74] Pérez de Ciriza, C., Moreno, M., Restituto, P., Bastarrika, G., Simón, I., Colina, I., et al. Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification. Clin. Biochem. 47 (2014), 272–278.
75. [75] Hosbond, S.E., Poulsen, T.S., Diederichsen, A.C., Nybo, M., Rasmussen, L.M., Mickley, H., Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand. Cardiovasc. J. 46 (2012), 203–211.
76. [76] Nascimento, M.M., Hayashi, S.Y., Riella, M.C., Lindholm, B., Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease. Braz. J. Med. Biol. Res. 47 (2014), 995–1002.
77. [77] Friões, F., Laszczynska, O., Almeida, P.B., Silva, N., Guimarães, J.T., Omland, T., et al. Prognostic value of osteoprotegerin in acute heart failure. Can. J. Cardiol. 31 (2015), 1266–1271.
78. [78] Bjerre, M., Hilden, J., Kastrup, J., Skoog, M., Hansen, J.F., Kolmos, H.J., et al. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. Scand. J. Clin. Lab. Invest. 74 (2014), 657–664.
79. [79] Lewis, J.R., Lim, W.H., Ueland, T., Wong, G., Zhu, K., Lim, E.M., et al. Elevated circulating osteoprotegerin and renal dysfunction predict 15-year cardiovascular and all-cause mortality: a prospective study of elderly women. PLoS One, 10, 2015, e0134266.
80. [80] Song, T.J., Kim, J., Yang, S.H., Park, J.H., Lee, H.S., Nam, C.M., et al. Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients. Biomarkers 17 (2012), 738–744.
81. [81] Di Bartolo, B.A., Schoppet, M., Mattar, M.Z., Rachner, T.D., Shanahan, C.M., Kavurma, M.M., Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc. Res. 91 (2011), 537–545.
82. [82] Zauli, G., Corallini, F., Bossi, F., Fischetti, F., Durigutto, P., Celeghini, C., et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110 (2007), 536–543.
83. [83] Mangan, S.H., Campenhout, A.V., Rush, C., Golledege, J., Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumour necrosis factor-a associated with induction of angiopoietin-2. Cardiovasc. Res. 76 (2007), 494–505.
84. [84] Uzui, H., Morishita, T., Nakano, A., Amaya, N., Fukuoka, Y., Ishida, K., et al. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. J. Cardiovasc. Pharmacol. Ther. 19 (2014), 304–309.
85. [85] Nellemann, B., Gormsen, L.C., Dollerup, J., et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care 30 (2007), 3122–3124.
86. [86] Mori, K., Jono, S., Emoto, M., et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Angiology 61 (2010), 86–91.
87. [87] Nezami, N., Safa, J., Eftekhar-Sadat, A.T., et al. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy. Clin. Biochem. 43 (2010), 1294–1299.
88. [88] Dimitrow, P.P., Jawień, M., Gackowski, A., The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. J. Heart Valve Dis. 20 (2011), 18–22.
89. [89] Davenport, C., Mahmood, W.A., Forde, H., Ashley, D.T., Agha, A., McDermott, J., et al. The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes. Eur. J. Endocrinol. 173 (2015), 53–61.
90. [90] Sodek, J., Ganss, B., McKee, M.D., Osteopontin. Crit. Rev. Oral Biol. Med. 11 (2000), 279–303.
91. [91] Fodor, D., Bondor, C., Albu, A., Simon, S.P., Craciun, A., Muntean, L., The value of osteopontin in the assessment of bone mineral density status in postmenopausal women. J. Investig. Med. 61 (2013), 15–21.
92. [92] Wei, Q.S., Huang, L., Tan, X., Chen, Z.Q., Chen, S.M., Deng, W.M., Serum osteopontin levels in relation to bone mineral density and bone turnover markers in postmenopausal women. Scand. J. Clin. Lab. Invest. 76 (2016), 33–39.
93. [93] Chang, I.C., Chiang, T.I., Yeh, K.T., Lee, H., Cheng, Y.W., Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos. Int. 21 (2010), 1401–1409.
94. [94] Kahles, F., Findeisen, H.M., Bruemmer, D., Osteopontin: a novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab. 3 (2014), 384–393.
95. [95] Giachelli, C.M., Bae, N., Almeida, M., et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest. 92 (1993), 1686–1696.
96. [96] Ikeda, T., Shirasawa, T., Esaki, Y., et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J. Clin. Invest. 92 (1993), 2814–2820.
97. [97] Lee, C.J., Wang, J.H., Chen, Y.C., Chen, M.L., Yang, C.F., Hsu, B.G., Serum osteopontin level correlates with carotid-femoral pulse wave velocity in geriatric persons. Biomed. Res. Int., 2014, 2014, 570698.
98. [98] Kato, R., Momiyama, Y., Ohmori, R., Tanaka, N., Taniguchi, H., Arakawa, K., et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler. Thromb. Vasc. Biol. 26 (2006), e1–e2.
99. [99] Li, X., Kramer, M.C., van der Loos, C.M., Koch, K.T., de Boer, O.J., Henriques, J.P., et al. A pattern of disperse plaque microcalcifications identifies a subset of plaques with high inflammatory burden in patients with acute myocardial infarction. Atherosclerosis 218 (2011), 83–89.
100. [100] Carbone, F., Vuilleumier, N., Burger, F., Roversi, G., Tamborino, C., Casetta, I., et al. Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke. Eur. J. Clin. Investig. 45 (2015), 579–586.
101. [101] Bjerre, M., Pedersen, S.H., Møgelvang, R., Lindberg, S., Jensen, J.S., Galatius, S., et al. High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention. Eur. J. Prev. Cardiol. 20 (2013), 922–929.
102. [102] Wada, T., McKee, M.D., Steitz, S., Giachelli, C.M., Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ. Res. 84 (1999), 166–178.
103. [103] Jono, S., Peinado, C., Giachelli, C.M., Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J. Biol. Chem. 275 (2000), 20197–20203.
104. [104] Kazanecki, C.C., Uzwiak, D.J., Denhardt, D.T., Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J. Cell. Biochem. 102 (2007), 912–924.
105. [105] Sainger, R., Grau, J.B., Poggio, P., Branchetti, E., Bavaria, J.E., Gorman, J.H. 3rd, et al. Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease. Biomarkers 17 (2012), 111–118.
106. [106] Lorenzen, J.M., Neunhöffer, H., David, S., Kielstein, J.T., Haller, H., Fliser, D., Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension—results from the EUTOPIA trial. Atherosclerosis 209 (2010), 184–188.
107. [107] Vassalle, C., Iervasi, G., New insights for matrix Gla protein, vascular calcification and cardiovascular risk and outcome. Atherosclerosis 235 (2014), 236–238.
108. [108] Luo, G., Ducy, P., McKee, M.D., Pinero, G.J., Loyer, E., Behringer, R.R., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 (1997), 78–81.
109. [109] Yao, Y., Bennett, B.J., Wang, X., Rosenfeld, M.E., Giachelli, C., Lusis, A.J., et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ. Res. 107 (2010), 485–494.
110. [110] O'Young, J., Liao, Y., Xiao, Y., Jalkanen, J., Lajoie, G., Karttunen, M., et al. Matrix Gla protein inhibits ectopic calcification by a direct interaction with hydroxyapatite crystals. J. Am. Chem. Soc. 133 (2011), 18406–18412.
111. [111] Sweatt, A., Sane, D.C., Hutson, S.M., Wallin, R., Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J. Thromb. Haemost. 1 (2003), 178–185.
112. [112] Delanaye, P., Krzesinski, J.M., Warling, X., Moonen, M., Smelten, N., Médart, L., et al. Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrol., 15, 2014, 145.
113. [113] Dalmeijer, G.W., van der Schouw, Y.T., Magdeleyns, E.J., Vermeer, C., Verschuren, W.M., Boer, J.M., et al. Matrix Gla protein species and risk of cardiovascular events in type 2 diabetic patients. Diabetes Care 36 (2013), 3766–3771.
114. [114] Pivin, E., Ponte, B., Pruijm, M., Ackermann, D., Guessous, I., Ehret, G., et al. Inactive matrix Gla-protein is associated with arterial stiffness in an adult population-based study. Hypertension 66 (2015), 85–92.
115. [115] Mayer, O. Jr., Seidlerová, J., Wohlfahrt, P., Filipovský, J., Vaněk, J., Cífková, R., et al. Desphospho-uncarboxylated matrix Gla protein is associated with increased aortic stiffness in a general population. J. Hum. Hypertens., May 28 2015, 10.1038/jhh.2015.55.
116. [116] Mayer O, Seidlerová J, Bruthans J, Filipovský J,Timoracká K, Vaněk J, Černá L, Wohlfahrt P, Cífková R, Theuwissen E, Vermeer C. Desphosho-uncarboxylated matrix gla-protein is associated with mortality risk in patients with chronic stable vascular disease. Atherosclerosis in press in.
117. [117] van den Heuvel, E.G., van Schoor, N.M., Lips, P., et al. Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease. Maturitas 77 (2014), 137–141.
118. [118] Schurgers, L.J., Barreto, D.V., Barreto, F.C., et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin. J. Am. Soc. Nephrol. 5 (2010), 568–575.
119. [119] Lieben, L., Carmeliet, G., Vitamin D signaling in osteocytes: effects on bone and mineral homeostasis. Bone 54 (2013), 237–243.
120. [120] Olauson, H., Vervloet, M.G., Cozzolino, M., Massy, Z.A., Ureña Torres, P., Larsson, T.E., New insights into the FGF23-Klotho axis. Semin. Nephrol. 34 (2014), 586–597.
121. [121] Jones, G., Prosser, D.E., Kaufmann, M., 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch. Biochem. Biophys. 523 (2012), 9–18.
122. [122] Quarles, L.D., Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp. Cell Res. 318 (2012), 1040–1048.
123. [123] Mazzaferro, S., Pasquali, M., Pirrò, G., Rotondi, S., Tartaglione, L., The bone and the kidney. Arch. Biochem. Biophys. 503 (2010), 95–102.
124. [124] Guo, Y.C., Yuan, Q., Fibroblast growth factor 23 and bone mineralisation. Int. J. Oral Sci. 7 (2015), 8–13.
125. [125] Nakatani, T., Ohnishi, M., Razzaque, M.S., Inactivation of Klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J. 23 (2009), 3702–3711.
126. [126] Scialla, J.J., Wolf, M., Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat. Rev. Nephrol. 10 (2014), 268–278.
127. [127] Scialla, J.J., Xie, H., Rahman, M., Anderson, A.H., Isakova, T., Ojo, A., et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J. Am. Soc. Nephrol. 25 (2014), 349–360.
128. [128] Hamano, T., Grunwald, J.E., Raj, D.S., Yang, W., He, J., Lash, J.P., et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J. Am. Soc. Nephrol. 25 (2014), 349–360.
129. [129] Gutierrez, O.M., Mannstadt, M., Isakova, T., Rauh-Hain, J.A., Tamez, H., Shah, A., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359 (2008), 584–592.
130. [130] Masson, S., Agabiti, N., Vago, T., Miceli, M., Mayer, F., Letizia, T., et al. The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk. J. Intern. Med. 277 (2015), 318–330.
131. [131] Kestenbaum, B., Sachs, M.C., Hoofnagle, A.N., Siscovick, D.S., Ix, J.H., Robinson-Cohen, C., et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ. Heart Fail.(7), 2014, 409–417.
132. [132] Mirza, M.A., Alsiö, J., Hammarstedt, A., Erben, R.G., Michaëlsson, K., Tivesten, A., et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 219–227.
133. [133] Isakova, T., Barchi-Chung, A., Enfield, G., Smith, K., Vargas, G., Houston, J., et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin. J. Am. Soc. Nephrol. 8 (2013), 1009–1018.
134. [134] Yilmaz, M.I., Sonmez, A., Saglam, M., Yaman, H., Kilic, S., Eyileten, T., et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am. J. Kidney Dis. 59 (2012), 177–185.
135. [135] Moe, S.M., Zidehsarai, M.P., Chambers, M.A., Jackman, L.A., Radcliffe, J.S., Trevino, L.L., et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6 (2011), 257–264.
136. [136] Seto, J., Busse, B., Gupta, H.S., Schäfer, C., Krauss, S., Dunlop, J.W., et al. Accelerated growth plate mineralization and foreshortened proximal limb bones in fetuin-A knockout mice. PLoS One, 7, 2012, e47338.
137. [137] Herrmann, M., Schäfer, C., Heiss, A., Gräber, S., Kinkeldey, A., Büscher, A., et al. Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor-A. Circ. Res. 111 (2012), 575–584.
138. [138] Smith, E.R., Hanssen, E., McMahon, L.P., Holt, S.G., Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS One, 8, 2013, e60904.
139. [139] Chailurkit, L., Kruavit, A., Rajatanavin, R., Ongphiphadhanakul, B., The relationship of fetuin-A and lactoferrin with bone mass in elderly women. Osteoporos. Int. 22:7 (Jul 2011), 2159–2164.
140. [140] Rasul, S., Ilhan, A., Reiter, M.H., Todoric, J., Farhan, S., Esterbauer, H., et al. Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes. Clin. Endocrinol. 76:4 (Apr 2012), 499–505.
141. [141] Pateinakis, P., Papagianni, A., Douma, S., Efstratiadis, G., Memmos, D., Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. BMC Nephrol., 14, 2013, 122.
142. [142] Akyuz, A., Oran, M., Alpsoy, S., Mutlu, L.C., Akkoyun, D.C., Guzel, S., et al. Association between serum fetuin-A levels, carotid artery stiffness, and intima-media thickness in patients with normotensive obstructive sleep apnea syndrome. Angiology 65 (2014), 607–613.
143. [143] de Jager, D.J., Vervloet, M.G., Dekker, F.W., Noncardiovascular mortality in CKD: an epidemiological perspective. Nat. Rev. Nephrol. 10 (2014), 208–214.
144. [144] Aydin, Z., Ozturk, S., Celik, C., Gursu, M., Karadag, S., Yamak, M., et al. The role of fetuin-A in cardiac functions and metabolism in peritoneal dialysis patients. Minerva Urol. Nefrol. 67 (2015), 375–382.
145. [145] Lee, C.T., Chua, S., Hsu, C.Y., Tsai, Y.C., Ng, H.Y., Kuo, C.C., et al. Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients. Dis. Markers 34 (2013), 229–235.
146. [146] Abdel-Wahab, A.F., Fathy, O., Al-Harizy, R., Negative correlation between fetuin-A and indices of vascular disease in systemic lupus erythematosus patients with and without lupus nephritis. Arab. J. Nephrol. Transplant. 6 (2013), 11–20.
147. [147] Schoppet, M., Rauner, M., Benner, J., Chapurlat, R., Hofbauer, L.C., Szulc, P., Serum fetuin-A levels and abdominal aortic calcification in healthy men - the STRAMBO study. Bone 79 (2015), 196–202.
148. [148] Scialla, J.J., Kao, W.H., Crainiceanu, C., Sozio, S.M., Oberai, P.C., Shafi, T., et al. Biomarkers of vascular calcification and mortality in patients with ESRD. Clin. J. Am. Soc. Nephrol. 9 (2014), 745–755.
149. [149] Sun, Q., Jiménez, M.C., Townsend, M.K., Rimm, E.B., Manson, J.E., Albert, C.M., et al. Plasma levels of fetuin-A and risk of coronary heart disease in US women: the Nurses’ Health Study. J. Am. Heart Assoc., 3, 2014, e000939.
150. [150] Schure, R., Costa, K.D., Rezaei, R., Lee, W., Laschinger, C., Tenenbaum, H.C., et al. Impact of matrix metalloproteinases on inhibition of mineralization by fetuin. J. Periodontal Res. 48 (2013), 357–366.
151. [151] Singh, M., Sharma, P.K., Garg, V.K., Mondal, S.C., Singh, A.K., Kumar, N., Role of fetuin-A in atherosclerosis associated with diabetic patients. J. Pharm. Pharmacol. 64 (2012), 1703–1708.
152. [152] Kahraman, A., Sowa, J.P., Schlattjan, M., Sydor, S., Pronadl, M., Wree, A., et al. Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. Clin. Sci. (Lond.) 125 (2013), 391–400.
153. [153] Pal, D., Dasgupta, S., Kundu, R., Maitra, S., Das, G., Mukhopadhyay, S., et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 18 (2012), 1279–1285.
154. [154] Akin, F., Celik, O., Ayca, B., Altun, I., Diker, V.O., Byk, I., et al. Associations of fibroblast growth factor 23 and fetuin-A with coronary plaque burden and plaque composition in young adults. J. Investig. Med. 63 (2015), 613–619.
155. [155] Yin, L., Cai, W.J., Zhu, L.Y., Li, J., Su, X.H., Wang, X.L., et al. Association of plasma Fetuin-A and clinical characteristics in patients with new-onset type 2 diabetes mellitus. Int. J. Clin. Exp. Med. 8 (2015), 991–999.
156. [156] Kadoglou, N.P., Kottas, G., Lampropoulos, S., Vitta, I., Liapis, C.D., Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy. Clin. Drug Investig. 34 (2014), 165–171.
157. [157] Hansen, D., Rasmussen, K., Rasmussen, L.M., Bruunsgaard, H., Brandi, L., The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study. BMC Nephrol., 15, 2014 Aug 12, 130, 10.1186/1471-2369-15-130.
158. [158] An, W.S., Lee, S.M., Son, Y.K., Kim, S.E., Kim, K.H., Han, J.Y., et al. Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients. Nutr. Res. 32 (2012), 495–502.
159. [159] Yamada, S., Tokumoto, M., Tsuruya, K., Tatsumoto, N., Noguchi, H., Kitazono, T., et al. Fetuin-A decrease induced by a low protein diet enhances vascular calcification in uremic rats with hyperphosphatemia. Am. J. Physiol. Ren. Physiol., Jul 15 2015, 10.1152/ajprenal.00017.2015.
160. [160] Brix, J.M., Stingl, H., Höllerl, F., Schernthaner, G.H., Kopp, H.P., Schernthaner, G., Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J. Clin. Endocrinol. Metab. 95 (2010), 4877–4881.
161. [161] Sallam, T., Cheng, H., Demer, L.L., Tintut, Y., Regulatory circuits controlling vascular cell calcification. Cell. Mol. Life Sci. 70 (2013), 3187–3197.
162. [162] London, G.M., Bone-vascular cross-talk. J. Nephrol. 25 (2012), 619–625.
163. [163] Schett, G., Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur. J. Clin. Investig. 41 (2011), 1361–1366.
164. [164] Vassalle, C., Bianchi, S., Battaglia, D., Landi, P., Bianchi, F., Carpeggiani, C., Elevated levels of oxidative stress as a prognostic predictor of major adverse cardiovascular events in patients with coronary artery disease. J. Atheroscler. Thromb. 19 (2012), 712–717.
165. [165] Vassalle, C., Pratali, L., Boni, C., Mercuri, A., Ndreu, R., An oxidative stress score as a combined measure of the pro-oxidant and anti-oxidant counterparts in patients with coronary artery disease. Clin. Biochem. 41 (2008), 1162–1167.
166. [166] Wang, K., Niu, J., Kim, H., Kolattukudy, P.E., Osteoclast precursor differentiation by MCPIP via oxidative stress, endoplasmic reticulum stress, and autophagy. J. Mol. Cell Biol. 3 (2011), 360–368.
167. [167] Suh, K.S., Choi, E.M., Rhee, S.Y., Kim, Y.S., Methylglyoxal induces oxidative stress and mitochondrial dysfunction in osteoblastic MC3T3-E1 cells. Free Radic. Res. 48 (2014), 206–217.
168. [168] Aikawa, E., Nahrendorf, M., Sosnovik, D., et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115 (2007), 377–386.
169. [169] Deuell, K.A., Callegari, A., Giachelli, C.M., Rosenfeld, M.E., Scatena, M., RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-α. J. Vasc. Res. 49 (2012), 510–521.
170. [170] Mazzone, A., Epistolato, M.C., De Caterina, R., Storti, S., Vittorini, S., Sbrana, S., et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J. Am. Coll. Cardiol. 43 (2004), 1670–1676.
171. [171] Mazzone, A., Epistolato, M.C., Gianetti, J., Castagnini, M., Sassi, C., Ceravolo, R., et al. Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease?. Am. J. Clin. Pathol. 126 (2006), 494–502.
172. [172] Viaene, L., Behets, G.J., Heye, S., Claes, K., Monbaliu, D., Pirenne, J., et al. Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporos. Int., Aug 21 2015 (PubMed PMID: 26294291).
173. [173] Avogaro, A., Rattazzi, M., Fadini, G.P., Ectopic calcification in diabetic vascular disease. Expert Opin. Ther. Targets 18 (2014), 595–609.
174. [174] Davies, M.R., Lund, R.J., Mathew, S., Hruska, K.A., Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J. Am. Soc. Nephrol. 16 (2005), 917–928.
175. [175] Marulanda, J., Gao, C., Roman, H., Henderson, J.E., Murshed, M., Prevention of arterial calcification corrects the low bone mass phenotype in MGP-deficient mice. Bone 57 (2013), 499–508.
176. [176] Román-García, P., Carrillo-López, N., Fernández-Martín, J.L., Naves-Díaz, M., Ruiz-Torres, M.P., Cannata-Andía, J.B., High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 46 (2010), 121–128.
177. [177] Murphy, W.A. Jr., Nedden, D., Gostner, P., Knapp, R., Recheis, W., Seidler, H., The iceman: discovery and imaging. Radiology 226 (2003), 614–629.
178. [178] Wilund, K.R., Tomayko, E.J., Evans, E.M., Kim, K., Ishaque, M.R., Fernhall, B., Physical activity, coronary artery calcium, and bone mineral density in elderly men and women: a preliminary investigation. Metabolism 57 (2008), 584–591.
179. [179] Tomayko, E.J., Chung, H.R., Wilund, K.R., Soy protein diet and exercise training increase relative bone volume and enhance bone microarchitecture in a mouse model of uremia. J. Bone Miner. Metab. 29 (2011), 682–690.
180. [180] Tomayko, E.J., Cachia, A.J., Chung, H.R., Wilund, K.R., Resveratrol supplementation reduces aortic atherosclerosis and calcification and attenuates loss of aerobic capacity in a mouse model of uremia. J. Med. Food 17 (2014), 278–283.
181. [181] Ibrahim, N., Mohamed, N., Shuid, A.N., Update on statins: hope for osteoporotic fracture healing treatment. Curr. Drug Targets 14 (2013), 1524–1532.
182. [182] Lin, S., Huang, J., Fu, Z., Liang, Y., Wu, H., Xu, L., et al. The effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in the high-fat-fed ovariectomized rats. Calcif. Tissue Int. 96 (2015), 541–551.
183. [183] Tan, J., Yang, N., Fu, X., Cui, Y., Guo, Q., Ma, T., et al. Single-dose local simvastatin injection improves implant fixation via increased angiogenesis and bone formation in an ovariectomized rat model. Med. Sci. Monit. 21 (2015), 1428–1439.
184. [184] Chen, Z.G., Cai, H.J., Jin, X., Lu, J.H., Wang, J., Fang, N.Y., Effects of atorvastatin on bone mineral density (BMD) and bone metabolism in elderly males with osteopenia and mild dyslipidemia: a 1-year randomized trial. Arch. Gerontol. Geriatr. 59 (2014), 515–521.
185. [185] Thabit, A., Alhifany, A., Alsheikh, R., Namnqani, S., Al-Mohammadi, A., Elmorsy, S., et al. Effect of simvastatin and atorvastatin on serum vitamin d and bone mineral density in hypercholesterolemic patients: a cross-sectional study. J. Osteoporos., 2014, 2014, 468397.
186. [186] Rajamannan, N.M., Atorvastatin attenuates bone loss and aortic valve atheroma in LDLR mice. Cardiology 132 (2015), 11–15.
187. [187] Li, Q., Kingman, J., Sundberg, J.P., Levine, M.A., Uitto, J., Dual effects of bisphosphonates on ectopic skin and vascular soft tissue mineralization versus bone microarchitecture in a mouse model of generalized arterial calcification of infancy. J. Invest. Dermatol., Sep 29 2015, 10.1038/jid.2015.377.